Abivax SA American Depositary Shares (ABVX) - Net Assets
Based on the latest financial reports, Abivax SA American Depositary Shares (ABVX) has net assets worth $455.01 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($584.09 Million) and total liabilities ($129.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Abivax SA American Depositary Shares liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $455.01 Million |
| % of Total Assets | 77.9% |
| Annual Growth Rate | 24.12% |
| 5-Year Change | 1654.56% |
| 10-Year Change | 702.25% |
| Growth Volatility | 759.81 |
Abivax SA American Depositary Shares - Net Assets Trend (2013–2025)
This chart illustrates how Abivax SA American Depositary Shares's net assets have evolved over time, based on quarterly financial data. Also explore how large is Abivax SA American Depositary Shares's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Abivax SA American Depositary Shares (2013–2025)
The table below shows the annual net assets of Abivax SA American Depositary Shares from 2013 to 2025. For live valuation and market cap data, see ABVX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $455.01 Million | +1021.16% |
| 2024-12-31 | $40.58 Million | -79.29% |
| 2023-12-31 | $196.01 Million | +2626.53% |
| 2022-12-31 | $7.19 Million | -72.28% |
| 2021-12-31 | $25.93 Million | +44.88% |
| 2020-12-31 | $17.90 Million | -3.72% |
| 2019-12-31 | $18.59 Million | -46.35% |
| 2018-12-31 | $34.66 Million | -28.07% |
| 2017-12-31 | $48.18 Million | -15.05% |
| 2016-12-31 | $56.72 Million | -20.97% |
| 2015-12-31 | $71.77 Million | +111.49% |
| 2014-12-31 | $33.94 Million | -0.25% |
| 2013-12-31 | $34.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Abivax SA American Depositary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 73816769700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $784.66K | 0.17% |
| Other Comprehensive Income | $2.31 Million | 0.51% |
| Other Components | $1.19 Billion | 261.55% |
| Total Equity | $455.01 Million | 100.00% |
Abivax SA American Depositary Shares Competitors by Market Cap
The table below lists competitors of Abivax SA American Depositary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mineral Resources Ltd
AU:MIN
|
$9.33 Billion |
|
Masimo Corporation
NASDAQ:MASI
|
$9.34 Billion |
|
Sunoco LP
NYSE:SUN
|
$9.34 Billion |
|
MGM Resorts International
NYSE:MGM
|
$9.34 Billion |
|
Chart Industries Inc
NYSE:GTLS
|
$9.32 Billion |
|
Jefferies Financial Group Inc
NYSE:JEF
|
$9.32 Billion |
|
CAVA Group, Inc.
NYSE:CAVA
|
$9.31 Billion |
|
Lynas Rare Earths Limited
F:LYIC
|
$9.31 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abivax SA American Depositary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 40,584,000 to 455,011,262, a change of 414,427,262 (1021.2%).
- Net loss of 322,836,959 reduced equity.
- New share issuances of 648,124,000 increased equity.
- Other comprehensive income increased equity by 2,383,017.
- Other factors increased equity by 86,757,204.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-322.84 Million | -70.95% |
| Share Issuances | $648.12 Million | +142.44% |
| Other Comprehensive Income | $2.38 Million | +0.52% |
| Other Changes | $86.76 Million | +19.07% |
| Total Change | $- | 1021.16% |
Book Value vs Market Value Analysis
This analysis compares Abivax SA American Depositary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 17.97x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 32.05x to 17.97x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $3.67 | $117.61 | x |
| 2014-12-31 | $3.66 | $117.61 | x |
| 2015-12-31 | $7.38 | $117.61 | x |
| 2016-12-31 | $5.83 | $117.61 | x |
| 2017-12-31 | $4.85 | $117.61 | x |
| 2018-12-31 | $3.39 | $117.61 | x |
| 2019-12-31 | $1.53 | $117.61 | x |
| 2020-12-31 | $1.25 | $117.61 | x |
| 2021-12-31 | $1.68 | $117.61 | x |
| 2022-12-31 | $0.38 | $117.61 | x |
| 2023-12-31 | $4.55 | $117.61 | x |
| 2024-12-31 | $0.64 | $117.61 | x |
| 2025-12-31 | $6.54 | $117.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abivax SA American Depositary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -70.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.28x
- Recent ROE (-70.95%) is above the historical average (-162.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -17.32% | -7970.18% | 0.00x | 1.13x | $-9.30 Million |
| 2014 | -14.97% | -36285.71% | 0.00x | 1.12x | $-8.47 Million |
| 2015 | -22.23% | -37985.71% | 0.00x | 1.06x | $-23.13 Million |
| 2016 | -25.23% | -11266.14% | 0.00x | 1.07x | $-19.98 Million |
| 2017 | -23.29% | -112230.00% | 0.00x | 1.12x | $-16.04 Million |
| 2018 | -45.66% | -87905.56% | 0.00x | 1.56x | $-19.29 Million |
| 2019 | -164.77% | -1531700.00% | 0.00x | 2.78x | $-32.49 Million |
| 2020 | -209.78% | -59604.76% | 0.00x | 3.98x | $-39.34 Million |
| 2021 | -163.70% | -114735.14% | 0.00x | 4.21x | $-45.05 Million |
| 2022 | -844.90% | -1325.33% | 0.06x | 10.51x | $-61.46 Million |
| 2023 | -75.37% | -3197.14% | 0.01x | 1.67x | $-167.34 Million |
| 2024 | -434.26% | -1633.08% | 0.05x | 5.06x | $-180.30 Million |
| 2025 | -70.95% | 0.00% | 0.00x | 1.28x | $-368.34 Million |
Industry Comparison
This section compares Abivax SA American Depositary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $45,300,000
- Average return on equity (ROE) among peers: -89.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -17.32% | 0.28x | $9.33 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more